Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177853 · ClinicalTrials.gov registry record · Phase 1
Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00177853 is a Phase 1 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 23 participants.
The verdict
NCT00177853, a Phase 1 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.
Interventions
- DRUG irinotecan
- DRUG celecoxib
- PROCEDURE concurrent radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177853
The ClinicalTrials.gov registry entry for NCT00177853 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which irinotecan is the first listed.
NCT00177853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177853 about?
NCT00177853 is a clinical study titled "Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer". The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest...
What is the current status of trial NCT00177853?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00177853?
The interventions under investigation include: irinotecan (DRUG), celecoxib (DRUG), concurrent radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00177853?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.